ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Presentation

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Jul 29, 2023 6:08am

110 Views

Post# 35562985

RE:Presentation

Trek1701 wrote: The latest corp presentation was recently posted. It includes the Acumen comparisons and data. It also mentions PMN trial data expected to be available mid-2023. The presentation is dated July 2023.

https://d1io3yog0oux5.cloudfront.net/_697be8b01c053496df8401248683965e/promisneurosciences/db/933/8795/pdf/PMN_Corp_Deck_072623.pdf

The Acumen INTERCEPT-AD Clinical Trial Phase 1 took 2 years to complete.
Study Start (Actual): 2021-06-21
Study Completion (Actual) 2023-06-12

Is this what we can expect for PMN-310 Clinical Phase 1 Study which has not even started the recruiting?

G1945V

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter